RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Recent research into newer treatments for type 2 diabetes recognized the role that incretin hormones play in both ... involved in this process are glucagon-like peptide-1 (GLP-1) and glucose ...

If you find yourself jolting awake in the early morning hours, it may not necessarily be due to unexplained insomnia. Instead ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...